Waters Corporation (0LTI.L)
USD 330.95
(5.07%)
USD 330.95
(5.07%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.02 Billion USD | -0.62% |
| 2022 | 1.01 Billion USD | 4.11% |
| 2021 | 958.42 Million USD | 23.95% |
| 2020 | 777.97 Million USD | -2.84% |
| 2019 | 822.09 Million USD | 1.28% |
| 2018 | 799.64 Million USD | 2.04% |
| 2017 | 783.97 Million USD | 22.93% |
| 2016 | 725.01 Million USD | 8.95% |
| 2015 | 668.23 Million USD | 7.6% |
| 2014 | 638.31 Million USD | 3.48% |
| 2013 | 597.03 Million USD | -1.33% |
| 2012 | 584.52 Million USD | -1.04% |
| 2011 | 597.61 Million USD | 16.94% |
| 2010 | 514.34 Million USD | 13.59% |
| 2009 | 454.91 Million USD | -12.2% |
| 2008 | 475.98 Million USD | 14.76% |
| 2007 | 402.19 Million USD | 10.46% |
| 2006 | 360.77 Million USD | 9.33% |
| 2005 | 326.84 Million USD | 3.3% |
| 2004 | 337.67 Million USD | 20.47% |
| 2003 | 253.93 Million USD | 1.09% |
| 2002 | 241 Million USD | -0.3% |
| 2001 | 183.47 Million USD | 10.52% |
| 2000 | 240.26 Million USD | 16.58% |
| 1999 | 206.1 Million USD | 13.68% |
| 1998 | 164.8 Million USD | 141.09% |
| 1997 | 58.7 Million USD | -33.21% |
| 1996 | 88.1 Million USD | 37.82% |
| 1995 | 72.9 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 192.39 Million USD | -45.12% |
| 2024 Q3 | 41.84 Million USD | 11.07% |
| 2024 Q2 | 238.43 Million USD | 22.74% |
| 2023 Q2 | 242.43 Million USD | 17.28% |
| 2023 Q1 | 206.71 Million USD | -34.84% |
| 2023 Q4 | 313.96 Million USD | 37.97% |
| 2023 FY | - USD | -0.62% |
| 2023 Q3 | 227.56 Million USD | -6.13% |
| 2022 Q3 | 225.11 Million USD | -4.37% |
| 2022 Q4 | 317.22 Million USD | 40.92% |
| 2022 FY | - USD | 4.11% |
| 2022 Q1 | 238.1 Million USD | -20.7% |
| 2022 Q2 | 235.39 Million USD | -1.14% |
| 2021 Q4 | 300.24 Million USD | 33.81% |
| 2021 FY | - USD | 23.95% |
| 2021 Q2 | 239.13 Million USD | 12.81% |
| 2021 Q3 | 224.39 Million USD | -6.16% |
| 2021 Q1 | 211.98 Million USD | -32.77% |
| 2020 Q3 | 188.23 Million USD | 1.25% |
| 2020 Q2 | 185.9 Million USD | 90.17% |
| 2020 FY | - USD | -2.84% |
| 2020 Q1 | 97.76 Million USD | -62.28% |
| 2020 Q4 | 315.29 Million USD | 67.5% |
| 2019 Q3 | 199.44 Million USD | -3.26% |
| 2019 FY | - USD | 1.28% |
| 2019 Q1 | 145.39 Million USD | -35.37% |
| 2019 Q2 | 206.16 Million USD | 41.8% |
| 2019 Q4 | 259.17 Million USD | 29.95% |
| 2018 Q4 | 224.95 Million USD | 13.18% |
| 2018 FY | - USD | 2.04% |
| 2018 Q2 | 204.56 Million USD | 19.15% |
| 2018 Q1 | 171.68 Million USD | -33.72% |
| 2018 Q3 | 198.76 Million USD | -2.83% |
| 2017 Q3 | 184.87 Million USD | 11.71% |
| 2017 FY | - USD | 22.93% |
| 2017 Q4 | 259.01 Million USD | 40.1% |
| 2017 Q1 | 125.59 Million USD | -41.37% |
| 2017 Q2 | 165.49 Million USD | 31.77% |
| 2016 Q4 | 214.21 Million USD | 38.92% |
| 2016 Q2 | 154.02 Million USD | 33.58% |
| 2016 Q1 | 115.3 Million USD | -39.84% |
| 2016 FY | - USD | 8.95% |
| 2016 Q3 | 154.2 Million USD | 0.12% |
| 2015 Q1 | 122.45 Million USD | -35.59% |
| 2015 Q3 | 138.41 Million USD | 4.21% |
| 2015 Q4 | 191.67 Million USD | 38.48% |
| 2015 FY | - USD | 7.6% |
| 2015 Q2 | 132.81 Million USD | 8.46% |
| 2014 Q1 | 91.4 Million USD | -48.88% |
| 2014 Q2 | 121.04 Million USD | 32.42% |
| 2014 Q3 | 141.43 Million USD | 16.85% |
| 2014 Q4 | 190.11 Million USD | 34.41% |
| 2014 FY | - USD | 3.48% |
| 2013 FY | - USD | -1.33% |
| 2013 Q4 | 178.8 Million USD | 47.06% |
| 2013 Q1 | 111.79 Million USD | -32.77% |
| 2013 Q3 | 121.58 Million USD | 7.13% |
| 2013 Q2 | 113.49 Million USD | 1.52% |
| 2012 Q1 | 112.7 Million USD | -37.97% |
| 2012 Q2 | 122.58 Million USD | 8.77% |
| 2012 Q3 | 128.17 Million USD | 4.56% |
| 2012 Q4 | 166.29 Million USD | 29.75% |
| 2012 FY | - USD | -1.04% |
| 2011 Q1 | 118.39 Million USD | -28.58% |
| 2011 FY | - USD | 16.94% |
| 2011 Q3 | 129.63 Million USD | 5.33% |
| 2011 Q4 | 181.7 Million USD | 40.16% |
| 2011 Q2 | 123.07 Million USD | 3.95% |
| 2010 Q2 | 108.17 Million USD | 13.87% |
| 2010 FY | - USD | 13.59% |
| 2010 Q4 | 165.77 Million USD | 56.07% |
| 2010 Q3 | 106.22 Million USD | -1.81% |
| 2010 Q1 | 94.99 Million USD | -32.98% |
| 2009 Q4 | 141.75 Million USD | 43.42% |
| 2009 FY | - USD | -12.2% |
| 2009 Q2 | 89.37 Million USD | -11.34% |
| 2009 Q3 | 98.83 Million USD | 10.58% |
| 2009 Q1 | 100.81 Million USD | -21.94% |
| 2008 FY | - USD | 14.76% |
| 2008 Q4 | 129.13 Million USD | 15.6% |
| 2008 Q3 | 111.71 Million USD | -0.32% |
| 2008 Q2 | 112.06 Million USD | 9.75% |
| 2008 Q1 | 102.11 Million USD | -28.86% |
| 2007 Q1 | 85.69 Million USD | -31.62% |
| 2007 Q3 | 82.91 Million USD | -7.91% |
| 2007 Q2 | 90.03 Million USD | 5.06% |
| 2007 Q4 | 143.54 Million USD | 73.12% |
| 2007 FY | - USD | 10.46% |
| 2006 FY | - USD | 9.33% |
| 2006 Q2 | 80.53 Million USD | 1.85% |
| 2006 Q1 | 79.07 Million USD | -25.56% |
| 2006 Q3 | 79.19 Million USD | -1.66% |
| 2006 Q4 | 125.32 Million USD | 58.25% |
| 2005 FY | - USD | 3.3% |
| 2005 Q2 | 78.05 Million USD | 13.21% |
| 2005 Q3 | 73.61 Million USD | -5.69% |
| 2005 Q4 | 106.22 Million USD | 44.3% |
| 2005 Q1 | 68.94 Million USD | -36.32% |
| 2004 FY | - USD | 20.47% |
| 2004 Q1 | 68.57 Million USD | -14.84% |
| 2004 Q2 | 71.5 Million USD | 4.27% |
| 2004 Q3 | 74.05 Million USD | 3.56% |
| 2004 Q4 | 108.27 Million USD | 46.22% |
| 2003 Q4 | 79.59 Million USD | 24.43% |
| 2003 FY | - USD | 1.09% |
| 2003 Q3 | 59.69 Million USD | 5.04% |
| 2003 Q1 | 53.04 Million USD | -35.11% |
| 2003 Q2 | 52.76 Million USD | 1.36% |
| 2002 Q4 | 72.61 Million USD | 62.08% |
| 2002 Q3 | 57.79 Million USD | 1.18% |
| 2002 Q2 | 57.24 Million USD | 1.29% |
| 2002 Q1 | 53.35 Million USD | 445.53% |
| 2002 FY | - USD | -0.3% |
| 2001 Q1 | 57.1 Million USD | -18.81% |
| 2001 Q2 | 58.47 Million USD | -2.78% |
| 2001 Q4 | 10.33 Million USD | -82.1% |
| 2001 Q3 | 57.75 Million USD | -1.23% |
| 2001 FY | - USD | 10.52% |
| 2000 Q4 | 74.08 Million USD | 24.49% |
| 2000 Q1 | 49.37 Million USD | -27.28% |
| 2000 Q2 | 57.29 Million USD | 16.04% |
| 2000 Q3 | 59.51 Million USD | 3.87% |
| 2000 FY | - USD | 16.58% |
| 1999 Q1 | 41.6 Million USD | -21.21% |
| 1999 FY | - USD | 13.68% |
| 1999 Q4 | 67.9 Million USD | 40.29% |
| 1999 Q3 | 48.4 Million USD | 0.0% |
| 1999 Q2 | 48.4 Million USD | 16.35% |
| 1998 FY | - USD | 141.09% |
| 1998 Q4 | 52.8 Million USD | 28.47% |
| 1998 Q3 | 41.1 Million USD | 7.59% |
| 1998 Q2 | 38.2 Million USD | -22.36% |
| 1998 Q1 | 32.7 Million USD | 23.93% |
| 1997 Q3 | -30.3 Million USD | -215.65% |
| 1997 Q4 | 39.7 Million USD | 231.02% |
| 1997 Q1 | 23.1 Million USD | 31.25% |
| 1997 FY | - USD | -33.21% |
| 1997 Q2 | 26.2 Million USD | 13.42% |
| 1996 FY | - USD | 37.82% |
| 1996 Q3 | 22.5 Million USD | -40.98% |
| 1996 Q2 | 24 Million USD | 135.5% |
| 1996 Q1 | 19.1 Million USD | -15.61% |
| 1996 Q4 | 22.5 Million USD | -36.69% |
| 1995 Q3 | 17.7 Million USD | -53.44% |
| 1995 Q1 | 16.5 Million USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| 1995 Q4 | 17.9 Million USD | 106.09% |
| 1995 Q2 | 20.9 Million USD | 13.82% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 90.535% |
| Dynavax Technologies Corporation | 9.66 Million USD | -10475.74% |
| Illumina, Inc. | -608 Million USD | 268.133% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 68.604% |
| Biogen Inc. | 2.37 Billion USD | 56.994% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 327.666% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 12.181% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 332.755% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -940.332% |
| Perrigo Company plc | 646.2 Million USD | -58.194% |
| uniQure N.V. | -253.1 Million USD | 503.892% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 395.906% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 1210.189% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 484.309% |
| bluebird bio, Inc. | -167.16 Million USD | 711.537% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 968.892% |
| Imunon, Inc. | -20.78 Million USD | 5018.86% |
| Myriad Genetics, Inc. | -67.8 Million USD | 1607.745% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | -145.674% |
| Nektar Therapeutics | -243.1 Million USD | 520.494% |
| Editas Medicine, Inc. | -163.11 Million USD | 726.698% |
| Verastem, Inc. | -83.16 Million USD | 1329.169% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 109.064% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 2400.466% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 1084.903% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 2841.869% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -229.457% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 1269.262% |
| Evolus, Inc. | -41.81 Million USD | 2544.992% |
| Adicet Bio, Inc. | -136.53 Million USD | 848.71% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 1261.847% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 78.036% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 781.01% |
| FibroGen, Inc. | -261.4 Million USD | 491.06% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 39.043% |
| OPKO Health, Inc. | -65.51 Million USD | 1660.307% |
| Homology Medicines, Inc. | -47.75 Million USD | 2240.571% |
| Geron Corporation | -174.78 Million USD | 684.872% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 548.118% |
| Exelixis, Inc. | 196.6 Million USD | -419.96% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 1113.866% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 1933.437% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 301.9% |
| Zoetis Inc. | 3.68 Billion USD | 72.259% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 554.352% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 2121.377% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 77.802% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 2933.133% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 544.438% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -843.698% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | -126.188% |
| Blueprint Medicines Corporation | -474.61 Million USD | 315.387% |
| Insmed Incorporated | -654.73 Million USD | 256.131% |
| TG Therapeutics, Inc. | 26.1 Million USD | -3816.67% |
| Incyte Corporation | 919.42 Million USD | -11.184% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 302.306% |